Evidence map›Paper›PMID 41671353›Full record

ArticleScience advances2026

E7

Jeongmin Hwang, Tonatiuh A Ocampo, Vinzenz Mayer, Janice Kang, Krishna S Paranandi, Young Jun Kim, Zhenyu Han, John P Cavaliere, Sergej Kudruk, Jochen H Lorch and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design Considerations for Potent DNA-Platform-Based Cancer Vaccines.Current opinion in biomedical engineering · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jeongmin HwangDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0001-8799-3209
Tonatiuh A OcampoInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0001-5443-9519
Vinzenz MayerDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0003-2782-2007
Janice KangDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0009-0007-0837-2406
Krishna S ParanandiInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0001-7487-1069
Young Jun KimInternational Institute for Nanotechnology, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-5125-3433
Zhenyu HanDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0003-3798-9345
John P CavaliereDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-3767-0345
Sergej KudrukDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-6402-0292
Jochen H LorchDepartment of Medicine, Hematology/Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0001-9781-6548
Chad A MirkinDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-6634-7627

Funding

Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic AcidsR01CA257926 · NCI · NORTHWESTERN UNIVERSITY · PI CHAD A. MIRKIN, Bin Zhang · 2022 to 2026
$2.5M
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.R01CA275430 · NCI · WASHINGTON UNIVERSITY · PI MIRKIN, CHAD A., STEGH, ALEXANDER H. · 2022 to 2025
$2.3M
NCI NIH HHS R01 CA257926NCI NIH HHS R01 CA275430
6 · The paper itself

Abstract

To develop effective nanostructured immunotherapeutics, identifying structural parameters that maximize immune response is essential. Spherical nucleic acids (SNAs) provide a modular platform for coordinated antigen-adjuvant delivery, where subtle structural differences can markedly influence potency. Herein, three SNAs were designed with HLA-A2-restricted HPV16 E7

Indexed as

Cancer VaccinesCD8-Positive T-LymphocytesPapillomavirus E7 ProteinsVaccines, DNAAnimalsDendritic CellsFemaleHLA-A2 AntigenHuman papillomavirus 16HumansLymphocyte ActivationMiceCancer VaccinesHLA-A2 Antigenoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsVaccines, DNA

Identifiers

PMID41671353
PMCPMC12893237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.